Welcome to the Luzhu Biotech Official Website.
CN /  EN  

ABOUT US

Established in November 2001, Luzhu Biotechnology (Luzhu Biotech) aims to excel in human medicine. With a main focus on the research and development (R&D) of vaccine and therapeutic bispecific antibody for human disease prevention, control and treatment, Luzhu Biotech has a strong research team that utilizes state-of-the-art technologies to develop and produce various biological products that meet clinical needs.

PRODUCTS AND R&D

R&D

Luzhu Biotech is committed to the R&D of novel antibodies and vaccines, and strives to provide high-quality and affordable medicine for the society.

PRODUCTION BASES

Luzhu Biotech has a pilot and scale-up workshop meeting GMP requirements in Beijing and two production sites: Zhuhai Site I and Zhuhai Site II.

PRODUCTION BASES

Luzhu Biotech has a pilot and scale-up workshop meeting GMP requirements in Beijing and two production sites: Zhuhai Site I and Zhuhai Site II.

PRESS CENTER

2022-04-19

Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using Lonza’s GS Xceed® Gene Expression System

Luzhu Biotech entered a licensing agreement to use Lonza’s GS Xceed® Gene Expression System with GS piggyBac® transposon technology....

| More

2021-08-30

Luzhu Biotech completed Series B financing of CNY 350 million


On August 30, 2021, Beijing Luzhu Biotechnology Co., Ltd. announced the completion of Series B financing of CNY 350 million....

| More

2021-08-03

Luzhu Biotech obtained clinical trial approval for "Recombinant Herpes Zoster Vaccine (CHO cells)"

On August 3, 2021, Luzhu Biotech obtained clinical trial approval letter for "Recombinant Herpes Zoster Vaccine (CHO cells)" (Approval number: 2021LP01212)....

| More

PRESS CENTER

Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using Lonza’s GS Xceed® Gene Expression System2022-04-19

Luzhu Biotech entered a licensing agreement to use Lonza’s GS Xceed® Gene Expression System with GS piggyBac® transposon technology....

Luzhu Biotech completed Series B financing of CNY 350 million2021-08-30

On August 30, 2021, Beijing Luzhu Biotechnology Co., Ltd. announced the completion of Series B financing of CNY 350 million....

Luzhu Biotech obtained clinical trial approval for "Recombinant Herpes Zoster Vaccine (CHO cells)"2021-08-03

On August 3, 2021, Luzhu Biotech obtained clinical trial approval letter for "Recombinant Herpes Zoster Vaccine (CHO cells)" (Approval number: 2021LP01212)....

CAREERS

JOB OPPOTUNITIES
ABOUT LUZHUPRODUCTSINVESTOR PRESS CENTERCONTACT US
COMPANY PROFILEPRODUCTS IN R&DNEWS
COMPANY MILESTONESIMMUNOREAGENT
HONOUROUT-LICENSED PRODUCTS
INTELLECTUAL PROPERTY
Copyright © 2021
Beijing Luzhu Biotechnology Co., Ltd.
All Rights Reserved.
京ICP备 10053635号-1      京公安网备 11011202001190号
ABOUT LUZHU
COMPANY PROFILECOMPANY MILESTONESHONOURINTELLECTUAL PROPERTY
PRODUCTS
PRODUCTS IN R&DIMMUNOREAGENTOUT-LICENSED PRODUCTS
INVESTOR
PRESS CENTER
NEWS
CONTACT US
Copyright © 2021 Beijing Luzhu Biotechnology Co., Ltd. All Rights Reserved.
京ICP备 10053635号-1
京公安网备 11011202001190号